Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

2.779 -0.081 (-2.83%)

Delayed Quote Updated: 12:27 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,668,300
Open	2.850
Bid (Size)	2.770 (26,500)
Ask (Size)	2.780 (9,400)
Prev. Close	2.860
Today's Range	2.750 - 2.850
52wk Range	2.560 - 6.440
Shares Outstanding	95,598,665
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise ↗

Today 7:02 EDT

Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic...

Via MarketBeat

Altimmune Q2 Earnings Call Highlights ↗

August 12, 2026

Altimmune (NASDAQ:ALT) said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing...

Via MarketBeat

Performance

YTD	-20.8%	-20.8%
1 Month	-10.6%	-10.6%
3 Month	-11.8%	-11.8%
6 Month	-10.9%	-10.9%
1 Year	-26.3%	-26.3%

More News

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial ↗

July 28, 2026

Via MarketBeat

Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near ↗

June 10, 2026

Via MarketBeat

Altimmune Inc (NASDAQ:ALT) Reports Q4 Earnings Miss Amid Key Pipeline Milestones ↗

March 05, 2026

Via Chartmill

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial ↗

June 04, 2026

Via MarketBeat

Altimmune (ALT) Q1 2026 Earnings Transcript ↗

May 13, 2026

Via The Motley Fool

Altimmune Q1 Earnings Call Highlights ↗

May 13, 2026

Via MarketBeat

InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

May 13, 2026

Via Investor Brand Network

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

From BioMedWire

Via GlobeNewswire

What's going on in today's pre-market session ↗

April 23, 2026

Via Chartmill

Stay updated with the stocks that are on the move in today's after-hours session. ↗

April 22, 2026

Via Chartmill

ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns ↗

March 05, 2026

Via Stocktwits

Altimmune (ALT) Q4 2025 Earnings Call Transcript ↗

March 05, 2026

Via The Motley Fool

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play ↗

February 26, 2026

Via The Motley Fool

Nasdaq, S&P 500 Futures Edge Higher Ahead Of Fed Decision, Mag 7 Earnings Kick Off: Why NVDA, ASML, ALT, AI, UUU Are On Traders' Radar Today ↗

January 28, 2026

Via Stocktwits

ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon ↗

January 27, 2026

Via Stocktwits

Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗

January 23, 2026

Via Stocktwits

ALT Stock Rallies 4% — What Does Retail Think? ↗

January 22, 2026

Via Stocktwits

Why Are Investors Looking At Altimmune Stock? ↗

January 05, 2026

Via Benzinga

Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug ↗

January 05, 2026

Via Stocktwits

Altimmune Stock Soars Over 10% Premarket On Positive Mid-Stage Data For Liver Disease Treatment Drug ↗

December 19, 2025

Via Stocktwits

Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment ↗

November 17, 2025

Via Stocktwits

Important Notice to Long-Term Shareholders of Altimmune, Inc. (NASDAQ: ALT); Five Below, Inc. (NASDAQ: FIVE); Flywire Corporation (NASDAQ: FLYW); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

October 16, 2025

From Grabar Law Office

Via GlobeNewswire

Frequently Asked Questions

Is Altimmune, Inc. - Common Stock publicly traded?

Yes, Altimmune, Inc. - Common Stock is publicly traded.

What exchange does Altimmune, Inc. - Common Stock trade on?

Altimmune, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Altimmune, Inc. - Common Stock?

The ticker symbol for Altimmune, Inc. - Common Stock is ALT on the Nasdaq Stock Market

What is the current price of Altimmune, Inc. - Common Stock?

The current price of Altimmune, Inc. - Common Stock is 2.779

When was Altimmune, Inc. - Common Stock last traded?

The last trade of Altimmune, Inc. - Common Stock was at 10/01/26 12:27 PM ET

What is the market capitalization of Altimmune, Inc. - Common Stock?

The market capitalization of Altimmune, Inc. - Common Stock is 265.68M

How many shares of Altimmune, Inc. - Common Stock are outstanding?

Altimmune, Inc. - Common Stock has 266M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.